CLDX Q1 2021 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$685,000-74.9% YoY

Gross Profit

-$12M-1756.9% margin

Operating Income

-$17M-2429.1% margin

Net Income

-$17M-2414.3% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-81.9%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$219M

Total Liabilities

$25M

Stockholders' Equity

$194M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$685,000	$3M	-74.9%
Gross Profit	-$12M	-$9M	-34.2%
Operating Income	-$17M	-$13M	-29.3%
Net Income	-$17M	-$13M	-31.0%

Revenue Segments

Grant

$682,000100%

Service

$3,0000%